Sanofi (SNY) Long-Term Deferred Tax (2009 - 2025)

Sanofi has disclosed Long-Term Deferred Tax across 17 years of filings, most recently posting $10.0 billion for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $10.0 billion, up 17.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.0 billion (up 17.7% YoY), and the FY2025 annual result was $10.0 billion, up 17.7% from the prior year.
• Long-Term Deferred Tax came in at $10.0 billion for Q4 2025 at Sanofi, up from $9.1 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $10.0 billion in Q4 2025 to a low of $5.1 billion in Q2 2021.
• The 5-year median for Long-Term Deferred Tax is $6.7 billion (2023), against an average of $7.0 billion.
• Across the five-year window, Long-Term Deferred Tax declined 4.02% in 2021 and climbed 27.24% in 2023, its largest moves.
• Sanofi's Long-Term Deferred Tax stood at $5.3 billion in 2021, then increased by 4.37% to $5.5 billion in 2022, then advanced by 25.96% to $6.9 billion in 2023, then rose by 23.12% to $8.5 billion in 2024, then grew by 17.7% to $10.0 billion in 2025.
• The last three Long-Term Deferred Tax figures came in at $10.0 billion (Q4 2025), $9.1 billion (Q2 2025), and $8.5 billion (Q4 2024), per Business Quant data.